CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 17 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-20 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Grant or award | +36,750 | 443,729 | ||
| 2023-11-08 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale 10b5-1 | −200 | $17.61 | $4K | 561,270 |
| 2023-11-03 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale 10b5-1 | −541 | $17.51 | $9K | 561,470 |
| 2023-11-02 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale 10b5-1 | −3,332 | $15.36 | $51K | 562,011 |
| 2023-11-02 | Harmon Cyrus Director | Sale 10b5-1 | −5,000 | $15.64 | $78K | 943,714 |
| 2023-11-01 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale 10b5-1 | −6,668 | $15.02 | $100K | 565,343 |
| 2023-10-31 | Harmon Cyrus Director | Sale 10b5-1 | −25,000 | $12.05 | $301K | 948,714 |
| 2023-10-16 | Garland J. Scott Director | Grant or award · Stock Option (Right to Buy) | +21,520 | 21,520 | ||
| 2023-10-16 | Garland J. Scott Director | Grant or award · Stock Option (Right to Buy) | +14,347 | 14,347 | ||
| 2023-09-29 | Harmon Cyrus Director | Sale 10b5-1 | −25,000 | $12.41 | $310K | 973,714 |
| 2023-09-19 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale 10b5-1 | −20,000 | $12.67 | $253K | 572,011 |
| 2023-09-14 | BVF PARTNERS L P/IL Director | Other acquisition | +99,556 | 99,556 | ||
| 2023-09-12 | Graham G. Walmsley Director | Purchase | +508,130 | $9.84 | $5.0M | 1,668,130 |
| 2023-09-12 | BVF PARTNERS L P/IL Director | Purchase | +775,278 | $9.84 | $7.6M | 4,688,954 |
| 2023-09-12 | BVF PARTNERS L P/IL Director | Purchase | +677,853 | $9.84 | $6.7M | 3,584,512 |
| 2023-09-12 | BVF PARTNERS L P/IL Director | Purchase | +52,801 | $9.84 | $520K | 524,151 |
| 2023-09-05 | Harmon Cyrus Director | Sale 10b5-1 | −10,000 | $11.62 | $116K | 998,714 |
| 2023-08-31 | Harmon Cyrus Director | Sale 10b5-1 | −15,000 | $9.36 | $140K | 1,008,714 |
| 2023-08-16 | Harmon Cyrus Director | Sale 10b5-1 | −15,000 | $10.14 | $152K | 1,023,714 |
| 2023-08-16 | Harmon Cyrus Director | Sale 10b5-1 | −15,000 | $10.14 | $152K | 1,023,714 |
Page 12 of 21 · 402 trades